Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 7905148, 8 pages
https://doi.org/10.1155/2017/7905148
Research Article

Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment

1Department of Neurology in Zabrze, Medical University of Silesia, 3-go Maja St. 13-15, 41-800 Zabrze, Poland
2Department of Histology and Embryology, Chair of the Morphological Sciences, University of Rzeszów, Leszka Czarnego 4, 35-615 Rzeszów, Poland
3Department of Analytical Biochemistry, Faculty of Biology and Agriculture, University of Rzeszów, ul. Zelwerowicza 4, 35-601 Rzeszów, Poland
4Department of Laryngology in Zabrze, Medical University of Silesia, ul. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland
5Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, 90-236 Łódź, Poland

Correspondence should be addressed to Izabela Sadowska-Bartosz; mf.atzcop@akswodasi

Received 22 May 2017; Accepted 24 September 2017; Published 18 October 2017

Academic Editor: Valentina Pallottini

Copyright © 2017 Monika Adamczyk-Sowa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Multiple sclerosis (MS) is a disease involving oxidative stress (OS). This study was aimed at examination of the effect of melatonin supplementation on OS parameters, especially oxidative protein modifications of blood serum proteins, in MS patients. The study included 11 control subjects, 14 de novo diagnosed MS patients with the relapsing-remitting form of MS (RRMS), 36 patients with RRMS receiving interferon beta-1b (250 μg every other day), and 25 RRMS patients receiving interferon beta-1b plus melatonin (5 mg daily). The levels of N′-formylkynurenine, kynurenine, dityrosine, carbonyl groups, advanced glycation products (AGEs), advanced oxidation protein products (AOPP), and malondialdehyde were elevated in nontreated RRSM patients. N′-Formylkynurenine, kynurenine, AGEs, and carbonyl contents were decreased only in the group treated with interferon beta plus melatonin, while dityrosine and AOPP contents were decreased both in the group of patients treated with interferon beta and in the group treated with interferon beta-1b plus melatonin. These results demonstrate that melatonin ameliorates OS in MS patients supporting the view that combined administration of interferon beta-1b and melatonin can be more effective in reducing OS in MS patients than interferon beta-1b alone.